Yi-Long Wu Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

11/2022	Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial.
11/2022	Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
11/2022	Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705).
10/2022	Perioperative targeted therapy for oncogene-driven NSCLC.
6/2022	Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study.
4/2022	Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer.
3/2022	INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance.
1/2022	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.
1/2022	What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer.
1/2022	Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yi-Long Wu Research Topics

Disease

198	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2022 - 01/2005
105	Neoplasms (Cancer) 11/2022 - 09/2007
78	Lung Neoplasms (Lung Cancer) 01/2022 - 09/2007
27	Disease Progression 01/2022 - 10/2009
26	Neoplasm Metastasis (Metastasis) 01/2022 - 07/2005
23	Adenocarcinoma of Lung 01/2022 - 01/2012
15	Diarrhea 01/2022 - 09/2009
14	Brain Neoplasms (Brain Tumor) 11/2022 - 07/2015
14	Adenocarcinoma 11/2019 - 05/2007
13	Exanthema (Rash) 11/2018 - 11/2008
10	Nausea 01/2022 - 11/2011
10	Neutropenia 10/2018 - 11/2008
9	Vomiting 01/2022 - 02/2014
8	Carcinoma (Carcinomatosis) 12/2020 - 01/2006
7	Fatigue 01/2018 - 10/2009
5	Stomatitis 02/2021 - 02/2014
5	Acne Vulgaris 01/2018 - 11/2008
4	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 01/2016
4	Vision Disorders (Hemeralopia) 10/2018 - 06/2013
4	Urinary Bladder Neoplasms (Bladder Cancer) 12/2015 - 03/2008
3	Pleural Effusion (Pleural Effusions) 01/2022 - 01/2020
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 09/2014
3	Edema (Dropsy) 01/2022 - 12/2014
3	Anemia 03/2021 - 10/2018
3	Paronychia 02/2021 - 02/2015
3	Dermatitis 02/2021 - 11/2017
3	Leukopenia 10/2018 - 09/2010
3	Alopecia (Baldness) 06/2013 - 11/2008
2	Pneumonia (Pneumonitis) 01/2022 - 11/2017
2	Sarcoma (Soft Tissue Sarcoma) 10/2021 - 07/2014
2	COVID-19 01/2021 - 01/2020
2	Genetic Predisposition to Disease (Genetic Predisposition) 01/2021 - 02/2016
2	Breast Neoplasms (Breast Cancer) 10/2020 - 02/2013
2	Infections 09/2020 - 01/2020

Drug/Important Bio-Agent (IBA)

91	ErbB Receptors (EGF Receptor)IBA 11/2022 - 01/2006
73	Tyrosine Kinase InhibitorsIBA 11/2022 - 09/2007
42	Gefitinib (Iressa)FDA Link 11/2022 - 05/2007
25	PlatinumIBA 12/2021 - 11/2008
21	Biomarkers (Surrogate Marker)IBA 11/2022 - 09/2007
20	Cisplatin (Platino)FDA LinkGeneric 12/2021 - 07/2013
19	CrizotinibIBA 11/2022 - 06/2013
18	osimertinibIBA 03/2022 - 01/2017
18	Pemetrexed (MTA)FDA Link 10/2021 - 10/2009
18	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 01/2005
17	Proteins (Proteins, Gene)FDA Link 12/2021 - 06/2004
16	AfatinibIBA 04/2022 - 02/2014
14	Pharmaceutical PreparationsIBA 01/2022 - 10/2009
14	Anaplastic Lymphoma KinaseIBA 11/2021 - 03/2014
13	Immune Checkpoint InhibitorsIBA 11/2022 - 01/2017
13	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 10/2009
13	Gemcitabine FDA Link 01/2019 - 03/2010
12	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 09/2009
11	B7-H1 AntigenIBA 01/2022 - 11/2018
11	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 05/2009
10	Alanine Transaminase (SGPT)IBA 03/2021 - 08/2011
9	Messenger RNA (mRNA)IBA 01/2022 - 09/2007
8	dacomitinibIBA 03/2021 - 11/2017
7	Docetaxel (Taxotere)FDA Link 12/2021 - 11/2008
6	LigandsIBA 01/2022 - 04/2016
6	pembrolizumabIBA 08/2021 - 12/2017
6	Aspartate Aminotransferases (Aspartate Transaminase)IBA 03/2021 - 11/2016
6	Phosphotransferases (Kinase)IBA 01/2017 - 09/2007
5	MicroRNAs (MicroRNA)IBA 01/2022 - 03/2016
5	Circulating Tumor DNAIBA 01/2022 - 12/2015
5	Bevacizumab (Avastin)FDA Link 01/2021 - 06/2012
4	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2016
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2022 - 01/2020
3	durvalumabIBA 01/2022 - 10/2020
3	Biological ProductsIBA 01/2022 - 03/2015
3	AntibodiesIBA 01/2022 - 01/2021
3	NivolumabIBA 12/2021 - 01/2019
3	icotinibIBA 12/2021 - 09/2013
3	ceritinibIBA 03/2021 - 01/2017
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2021 - 01/2018
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 10/2009
3	Etoposide (VP 16)FDA LinkGeneric 10/2019 - 11/2016
3	VaccinesIBA 10/2011 - 06/2004
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2009
2	abivertinibIBA 01/2022 - 05/2019
2	Irinotecan (Camptosar)FDA LinkGeneric 12/2021 - 09/2010
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2021 - 07/2014
2	capmatinibIBA 04/2021 - 11/2018
2	Coal (Coals)IBA 01/2021 - 03/2015
2	Coloring Agents (Dyes)IBA 01/2021 - 10/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 06/2012
2	tislelizumabIBA 12/2020 - 01/2020
2	ORALIT (ORS)IBA 01/2020 - 10/2012
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 11/2011

Therapy/Procedure

71	Therapeutics 10/2022 - 05/2007
67	Drug Therapy (Chemotherapy) 11/2022 - 07/2005
18	Immunotherapy 01/2022 - 01/2009
8	Chemoradiotherapy 01/2022 - 08/2015
8	Neoadjuvant Therapy 01/2021 - 07/2005
6	Precision Medicine 01/2019 - 12/2009
5	Radiotherapy 10/2020 - 11/2011
3	Adjuvant Chemotherapy 01/2022 - 01/2017
3	Consolidation Chemotherapy 10/2019 - 08/2015
3	Lymph Node Excision (Lymph Node Dissection) 10/2017 - 08/2016
2	Drug Tapering 01/2022 - 03/2021
2	Aftercare (After-Treatment) 01/2021 - 06/2015